Bavisotto, Linda M <br/><br/>
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.  [electronic resource] 

 -  Journal of clinical pharmacology  Apr 2011 
 - 561-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1177/0091270010370588  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aryl Hydrocarbon Hydroxylases--antagonists & inhibitors<br/>Benzoates--administration & dosage<br/>Coumarins--administration & dosage<br/>Cytochrome P-450 CYP2C9<br/>Cytochrome P-450 CYP3A<br/>Cytochrome P-450 CYP3A Inhibitors<br/>Drug Interactions<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Fluconazole--pharmacology<br/>Humans<br/>Male<br/>NAD(P)H Dehydrogenase (Quinone)--antagonists & inhibitors<br/>Warfarin--administration & dosage